Baricitinib in patients with severe pneumonia due to COVID-19 in Veracruz, Mexico
- Journal of Anesthesia & Critical Care: Open Access
-
Luis Del Carpio-Orantes, Sergio García-Méndez, César López-Guzmán, Gustavo Miguel Zamudio-Severino, Jesús Salvador Sánchez-Díaz, Benito Navarrete-Espinoza, Miguel Ángel Rivera-Viñas, Arturo Salas-González, Elisa Estefanía Aparicio-Sánchez, Orlando Israel Segura-Rodríguez, Omar García-Hernández, Andrés Realino Velasco-Caicero, Alejandro Escobar-Huerta, Ernesto Javier Pacheco-Pérez, Olga González-Segovia, Azael Ahumada-Zamudio, Edna Rosario Contreras-Sánchez, Andrés Aguilar-Silva, Luis Jaime Medrano-Ríos
Abstract
Patients affected by COVID-19 pneumonia who present severe symptoms with manifest hypoxemia and cytokine storm have a high mortality rate, which is why therapies focused on reducing inflammation and improving lung function have been used, being one of them Baricitinib.
Keywords
Baricitinib; pneumonia; COVID-19
